MAG
AMLX icon

Millrace Asset Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Millrace Asset Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-19,496
Closed -$357K – 68
2023
Q3 		$357K Buy
+19,496
New +$412K 0.44% 54

Other funds holding AMLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millrace Asset Group's AMLX Position: Q4 2023 in Review

Millrace Asset Group sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2023, closing a stake of 19,496 shares — an estimated $357K sold.

Millrace Asset Group first reported a position in AMLX in Q3 2023 and held it in 1 quarter. The position peaked at $357K in Q3 2023. 178 funds tracked by Wall St. Rank hold AMLX as of Q4 2023.

  • Millrace Asset Group reported no remaining Amylyx Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Millrace Asset Group sold 19,496 Amylyx Pharmaceuticals shares in Q4 2023, an estimated $357K.
  • Millrace Asset Group first reported a position in Amylyx Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Millrace Asset Group's Amylyx Pharmaceuticals position peaked at $357K in Q3 2023.
  • 178 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2023.

Based on Millrace Asset Group's 13F filing for Q4 2023, filed 12 Feb 2024.